Literature DB >> 24366360

The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.

Zachary R Hunter1, Lian Xu, Guang Yang, Yangsheng Zhou, Xia Liu, Yang Cao, Robert J Manning, Christina Tripsas, Christopher J Patterson, Patricia Sheehy, Steven P Treon.   

Abstract

The genetic basis for Waldenström macroglobulinemia (WM) remains to be clarified. Although 6q losses are commonly present, recurring gene losses in this region remain to be defined. We therefore performed whole genome sequencing (WGS) in 30 WM patients, which included germline/tumor sequencing for 10 patients. Validated somatic mutations occurring in >10% of patients included MYD88, CXCR4, and ARID1A that were present in 90%, 27%, and 17% of patients, respectively, and included the activating mutation L265P in MYD88 and warts, hypogammaglobulinemia, infection, and myelokathexis-syndrome-like mutations in CXCR4 that previously have only been described in the germline. WGS also delineated copy number alterations (CNAs) and structural variants in the 10 paired patients. The CXCR4 and CNA findings were validated in independent expansion cohorts of 147 and 30 WM patients, respectively. Validated gene losses due to CNAs involved PRDM2 (93%), BTG1 (87%), HIVEP2 (77%), MKLN1 (77%), PLEKHG1 (70%), LYN (60%), ARID1B (50%), and FOXP1 (37%). Losses in PLEKHG1, HIVEP2, ARID1B, and BCLAF1 constituted the most common deletions within chromosome 6. Although no recurrent translocations were observed, in 2 patients deletions in 6q corresponded with translocation events. These studies evidence highly recurring somatic events, and provide a genomic basis for understanding the pathogenesis of WM.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24366360     DOI: 10.1182/blood-2013-09-525808

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  124 in total

1.  Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization.

Authors:  Monika Avbelj; Olaf-Oliver Wolz; Ota Fekonja; Mojca Benčina; Matej Repič; Janez Mavri; Jens Krüger; Charlotta Schärfe; Magno Delmiro Garcia; Gabriela Panter; Oliver Kohlbacher; Alexander N R Weber; Roman Jerala
Journal:  Blood       Date:  2014-10-30       Impact factor: 22.113

2.  Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia.

Authors:  I M Ghobrial; R Redd; P Armand; R Banwait; E Boswell; S Chuma; D Huynh; A Sacco; A M Roccaro; A Perilla-Glen; K Noonan; M MacNabb; H Leblebjian; D Warren; P Henrick; J J Castillo; P G Richardson; J Matous; E Weller; S P Treon
Journal:  Leukemia       Date:  2015-07-03       Impact factor: 11.528

Review 3.  The role of G protein-coupled receptors in lymphoid malignancies.

Authors:  Adrienne Nugent; Richard L Proia
Journal:  Cell Signal       Date:  2017-08-09       Impact factor: 4.315

4.  Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.

Authors:  Patrizia Mondello; Elliott J Brea; Elisa De Stanchina; Eneda Toska; Aaron Y Chang; Myles Fennell; Venkatraman Seshan; Ralph Garippa; David A Scheinberg; José Baselga; Hans-Guido Wendel; Anas Younes
Journal:  JCI Insight       Date:  2017-03-23

5.  Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.

Authors:  C Baer; F Dicker; W Kern; T Haferlach; C Haferlach
Journal:  Leukemia       Date:  2016-11-14       Impact factor: 11.528

6.  A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.

Authors:  Constantine S Tam; Stephen Opat; Shirley D'Sa; Wojciech Jurczak; Hui-Peng Lee; Gavin Cull; Roger G Owen; Paula Marlton; Björn E Wahlin; Ramón Garcia Sanz; Helen McCarthy; Stephen Mulligan; Alessandra Tedeschi; Jorge J Castillo; Jaroslaw Czyz; Carlos Fernández de Larrea; David Belada; Edward Libby; Jeffrey V Matous; Marina Motta; Tanya Siddiqi; Monica Tani; Marek Trneny; Monique C Minnema; Christian Buske; Veronique Leblond; Judith Trotman; Wai Y Chan; Jingjing Schneider; Sunhee Ro; Aileen Cohen; Jane Huang; Meletios Dimopoulos
Journal:  Blood       Date:  2020-10-29       Impact factor: 22.113

7.  Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström's Macroglobulinemia.

Authors:  Lisa A Raedler
Journal:  Am Health Drug Benefits       Date:  2016-03

8.  Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome.

Authors:  Monique C Minnema; Eva Kimby; Shirley D'Sa; Luc-Matthieu Fornecker; Stéphanie Poulain; Tom J Snijders; Efstathios Kastritis; Stéphane Kremer; Aikaterini Fitsiori; Laurence Simon; Frédéric Davi; Michael Lunn; Jorge J Castillo; Christopher J Patterson; Magali Le Garff-Tavernier; Myrto Costopoulos; Véronique Leblond; Marie-José Kersten; Meletios A Dimopoulos; Steven P Treon
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

9.  Comparative genomics of CXCR4MUT and CXCR4WT single cells in Waldenström's macroglobulinemia.

Authors:  Cristina Jiménez; Lian Xu; Nickolas Tsakmaklis; Maria G Demos; Amanda Kofides; Gloria G Chan; Maria Luisa Guerrera; Jiaji G Chen; Xia Liu; Manit Munshi; Christopher J Patterson; Guang Yang; Jorge J Castillo; Steven P Treon; Zachary R Hunter
Journal:  Blood Adv       Date:  2020-09-22

10.  Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.

Authors:  Lian Xu; Zachary R Hunter; Nicholas Tsakmaklis; Yang Cao; Guang Yang; Jie Chen; Xia Liu; Sandra Kanan; Jorge J Castillo; Yu-Tzu Tai; James L Zehnder; Jennifer R Brown; Ruben D Carrasco; Ranjana Advani; Jean M Sabile; Kimon Argyropoulos; M Lia Palomba; Enrica Morra; Alessandra Trojani; Antonino Greco; Alessandra Tedeschi; Marzia Varettoni; Luca Arcaini; Nikhil M Munshi; Kenneth C Anderson; Steven P Treon
Journal:  Br J Haematol       Date:  2015-12-13       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.